Dropout rates did not differ between antidepressants .
The latter study showed very promising results of  sertraline  in children and adolescents with GAD , which warrants its replication in larger sample s. REVIEW ER 'S CONCLUSIONS The available evidence suggests that antidepressants are superior to placebo in treating GAD .
There is also evidence from placebo-controlled trials suggesting that these drugs are well tolerated by GAD patients .
Further trials of antidepressants for GAD will help to demonstrate which antidepressants should be used for which patients
BACKGROUND Pharmacological treatments have been successfully used to treat  Generalized Anxiety Disorder ( GAD ) .
The mainstay for the pharmacological treatment of GAD in past decades has been the use of benzodiazepine and non benzodiazepine anxiolytics .
Data emerging over the last two decades have shown that antidepressants may be equally effective to anxiolytics for treating GAD .
The use of antidepressants for treating GAD may be advantageous , due to the fact that GAD presents a high co morbidity ratio with major depressive disorder ( 62 % ) and dysthymia ( 37 % ) .
OBJECTIVES To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder .
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.
OBJECTIVE Patients with generalized anxiety disorder ( N=107 ) who had been long-term benzodiazepine users ( average duration of use=8.5 years ) were enrolled in a benzodiazepine discontinuation program that assessed the effectiveness of concomitant imipramine ( 180 mg/day ) and buspirone ( 38 mg/day ) compared to placebo in facilitating benzodiazepine discontinuation . METHOD After a benzodiazepine stabilization period taking either diazepam , lorazepam , or alprazolam , patients were treated for 4 weeks with imipramine , buspirone , or placebo under double-blind conditions while benzodiazepine intake was kept stable ( treatment phase ) . Patients then entered a 4 - 6 week benzodiazepine taper and a 5-week posttaper phase with imipramine , buspirone , and placebo treatment being continued until 3 weeks into the posttaper phase , at which time all patients were switched to placebo for 2 weeks .  Benzodiazepine plasma levels were assayed weekly . Benzodiazepine-free status was assessed 3 and 12 months posttaper . RESULTS Study subjects were long-term benzodiazepine users with an average of three unsuccessful prior taper attempts . The success rate of the taper in this study was significantly higher for patients who received imipramine ( 82.6 % ) , and nonsignificantly higher for patients who received buspirone ( 67.9 % ) , than for patients who received placebo ( 37.5 % ) . The imipramine effect remained highly significant even after the analysis adjusted for three other independent predictors of taper success : benzodiazepine dose , level of anxious symptoms at baseline , and duration of benzodiazepine therapy . CONCLUSIONS Management of benzodiazepine discontinuation can be facilitated significantly by co-prescribing imipramine before and during the benzodiazepine taper . Daily benzodiazepine dose , severity of baseline symptoms of anxiety and depression , and duration of benzodiazepine use were additional significant predictors of successful taper outcome
Dropout rates did not differ between antidepressants .
The latter study showed very promising results of  sertraline  in children and adolescents with GAD , which warrants its replication in larger sample s. REVIEW ER 'S CONCLUSIONS The available evidence suggests that antidepressants are superior to placebo in treating GAD .
There is also evidence from placebo-controlled trials suggesting that these drugs are well tolerated by GAD patients .
Further trials of antidepressants for GAD will help to demonstrate which antidepressants should be used for which patients
BACKGROUND Pharmacological treatments have been successfully used to treat  Generalized Anxiety Disorder ( GAD ) .
The mainstay for the pharmacological treatment of GAD in past decades has been the use of benzodiazepine and non benzodiazepine anxiolytics .
Data emerging over the last two decades have shown that antidepressants may be equally effective to anxiolytics for treating GAD .
The use of antidepressants for treating GAD may be advantageous , due to the fact that GAD presents a high co morbidity ratio with major depressive disorder ( 62 % ) and dysthymia ( 37 % ) .
OBJECTIVES To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder .